Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP

NCT01225276 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Study Terminated.priority changes in product development.

Conditions

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Interventions

DRUG: NewGam 10%
DRUG: Placebo
DRUG: NewGam 10%
DRUG: NewGam 10%

Sponsor

Octapharma